School of Medicine
Showing 381-400 of 707 Results
-
AC Matin
Member, Cardiovascular Institute
Current Research and Scholarly Interests1. Improvement of our newly discovered cancer prodrug regimen that permits noninvaisve visualization of drug activation. 2. Tracking tumors & cancer metastases using bacterial magnetite and newly developed single-cell tracking by MRI. 3. Molecular basis of bacterial planktonic and biofilm antibiotic resistance on Earth and under space microgravity -- development of new countermeasures; 4. Bioremediation.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC). -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
D. Craig Miller, M.D.
Thelma and Henry Doelger Professor of Cardiovascular Surgery, Emeritus
Current Research and Scholarly InterestsCardiac and heart valve disease with experimental laboratory large animal projects focused on the investigation of left ventricular and cardiac mechanics, bioenergetics, and LV and mitral valve physiology and pathophysiology. Current thrust is aimed at understanding the mitral valve and subvalvular mitral apparatus and transmural LV wall strains, thickening, and myolaminar fiber-sheet mechanics.
Clinical research interests include thoracic aortic diseases (aortic dissection, aneurysm) and cardiac valvular disease, including surgical treatment, endovascular thoracic aortic stent-graft repair, mitral valve repair, and valve-sparing aortic root replacement. -
Lloyd B. Minor, MD
The Carl and Elizabeth Naumann Dean of the School of Medicine, Vice President for Medical Affairs, Stanford University, Professor of Otolaryngology - Head and Neck Surgery and Professor of Neurobiology and of Bioengineering, by courtesy
Current Research and Scholarly InterestsThrough neurophysiological investigations of eye movements and neuronal pathways, Dr. Minor has identified adaptive mechanisms responsible for compensation to vestibular injury in a model system for studies of motor learning. Following his discovery of superior canal dehiscence, he published a description of the disorder’s clinical manifestations and related its cause to an opening in the bone covering of the superior canal. He subsequently developed a surgical procedure to correct the problem.
-
R. Scott Mitchell
Professor of Cardiothoracic Surgery at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsResearch Interests: Disease of the aorta, congenital and acquired. Treatment of aortic pathology, including development of stent graft systems. Patterns of disease in patients treated with mediastinal radiation. Valvular heart disease, especially aortopathy associated with congenital bicuspid aortic valve.
-
Edward Mocarski
Professor of Microbiology and Immunology, Emeritus
Current Research and Scholarly InterestsMy research interests focused on the biology and pathogenesis of cytomegalovirus (CMV), an opportunistic pathogen that causes significant disease worldwide, reporting discoveries in areas of CMV gene regulation, DNA replication and packaging, maturation, impact on the host cell, disease pathogenesis, latency and reactivation, host cell death signaling and chemokine system. In the last 20 years of my academic career, we studied viral cell death suppressors and discovered ZBP1-RIPK3 necroptosis.
-
Daria Mochly-Rosen
George D. Smith Professor of Translational Medicine
Current Research and Scholarly InterestsTwo areas: 1. Using rationally-designed peptide inhibitors to study protein-protein interactions in cell signaling. Focus: protein kinase C in heart and large GTPases regulating mitochondrial dynamics in neurodegdenration. 2. Using small molecules (identified in a high throughput screens and synthetic chemistry) as activators and inhibitors of aldehyde dehydrogenases, a family of detoxifying enzymes, and glucose-6-phoshate dehydrogenase, in normal cells and in models of human diseases.
